z-logo
Premium
Opportunities and challenges of pharmacotherapy for pulmonary arterial hypertension in children
Author(s) -
Kam Charissa W.,
Ruiz Fadel E.
Publication year - 2021
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/ppul.25101
Subject(s) - medicine , pulmonary hypertension , intensive care medicine , pharmacotherapy , clinical trial , multidisciplinary approach , disease , medline , multidisciplinary team , pediatrics , sociology , political science , law , social science , nursing
Pediatric pulmonary hypertension (PAH) is a rare disease that carries a poor prognosis if left untreated. Although there are published guidelines for the treatment of children with pulmonary hypertension, due to the limited number of robust pediatric clinical trials, recommendations are often based on limited data or clinical experience. Furthermore, many practical aspects of care, particularly for the pediatric patient, are learned through experience and best navigated with a multidisciplinary team. While newer PAH therapies have been approved for adults, there is still limited but expanding experience in pediatrics. This new information will help improve the targets of goal‐oriented therapy. Lastly, this review highlights practical aspects in the use of the different therapies available for the treatment of pediatric pulmonary hypertension.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here